Cover Image

Editorial: UDCA Dosing in PBC—Between Guideline Adherence and Clinical Reality: Authors' Reply

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Ellen Werner, Maria C. B. van Hooff, Adriaan J. van der Meer
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: UDCA Dosing in PBC – Between Guideline Adherence and Clinical Reality
by: Helena Hernández‐Évole, et al.
Published: (2026)

Editorial: TIPS in the Era of Aging and Metabolic Comorbidity—Rethinking Risks and Rewards. Authors Reply
by: Michelle Spaan, et al.
Published: (2026)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
by: J. M. Schattenberg, et al.
Published: (2026)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
by: Hong‐Li Liu, et al.
Published: (2026)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
by: Benedikt Silvester Hofer, et al.
Published: (2024)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
by: Cristina Rubín de Célix, et al.
Published: (2025)

Editorial: Resecting Assumptions—Do Proctocolectomy Guidelines Hold Up? Author's Reply
by: Erik Lundqvist, et al.
Published: (2025)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
by: Shuaibing Ying, et al.
Published: (2026)

Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply
by: Nikolaj Torp, et al.
Published: (2025)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
by: Ramin Ebrahimi, et al.
Published: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
by: Raj Vuppalanchi, et al.
Published: (2025)

Editorial: Clinical Impact of Lipid Profile Change After DAA Treatment in CHC Patients—Authors' Reply
by: Zahra Sarrafan‐Chaharsoughi, et al.
Published: (2025)

Letter: Methodological Gaps Undermine Conclusions on Electronic Nose Use for Colorectal Cancer Detection—Authors' Reply
by: Milou. L. M. van Riswijk, et al.
Published: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
by: Bingqiong Wang, et al.
Published: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
by: Jianhui Zhao, et al.
Published: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
by: Jeongkuk Seo, et al.
Published: (2024)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
by: Máté Szilcz, et al.
Published: (2025)

Editorial: The Milan Score as Supportive Evidence of Gastro‐Oesophageal Reflux Disease. Authors' Reply
by: Stefano Siboni, et al.
Published: (2026)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
by: Fai Fai Ho, et al.
Published: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
by: Suprabhat Giri, et al.
Published: (2025)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply
by: Ryan M. Mathias, et al.
Published: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
by: Federica Tavaglione, et al.
Published: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
by: Parul Tandon, et al.
Published: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
by: Bharati Kochar, et al.
Published: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
by: David Mehdi Asgher Niazi, et al.
Published: (2026)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
by: Jeffrey D McCurdy, et al.
Published: (2025)

Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC. Authors' Reply
by: Natassia Tan, et al.
Published: (2025)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC—Authors' Reply
by: Subin Heo, et al.
Published: (2025)

Letter: Dose and Donor Matter—Determining the Optimal Strategy for Faecal Microbiota Transplantation in Clostridioides difficile Infection. Authors' Reply
by: Sara Ellegaard Paaske, et al.
Published: (2026)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
by: A. B. Fons, et al.
Published: (2026)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
by: Chia‐Chih Kuo, et al.
Published: (2025)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
by: Daniel Q. Huang, et al.
Published: (2026)

Editorial: The Devil Is in the Detail—Interpreting the Findings of Network Meta‐Analyses. Authors' Reply
by: Mohammad Shehab, et al.
Published: (2025)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
by: Lucie Simonis, et al.
Published: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
by: Mary Yue Wang, et al.
Published: (2026)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
by: Jiong Yu, et al.
Published: (2024)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
by: María Chaparro, et al.
Published: (2024)

Editorial: Ulcerative Colitis Management in the Biologic Era–Data From the English Healthcare Databases. Authors' Reply
by: J. Couch, et al.
Published: (2025)

Editorial: Do we Need to Adapt GERD Metrics Based on the Population Being Evaluated? Authors' Reply
by: Walter W. Chan, et al.
Published: (2026)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
by: Lukas Burghart, et al.
Published: (2026)